Area of research
Genetics · Molecular Biology
Research interest
Research interests include Virus-based gene therapy research, CAR-T cell therapy research, RNA Interference and Gene Delivery, and CRISPR and Genetic Engineering.
Baboon endogenous retrovirus (ERV) envelope pseudotyped lentiviral vectors outperform human ERV lentivectors for transduction of T, B, NK and HSPCs.
Call for preserving specialized knowledge and contributions of the CAT to advancing ATMPs in Europe
Securing raw materials, reagents, and consumable supplies in the academic bioproduction UNITC network: because the chain is only as strong as its weakest link.
Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trials.
Identification of the conditions and minimum requirements necessary for the release of autologous fresh CAR T-cell products under hospital exemption: a position paper from the WP-bioproduction of the UNITC consortium.
European survey on CAR T-Cell analytical methods from apheresis to post-infusion immunomonitoring.
Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium.
Combined effects of restriction factors and transduction adjuvants on lentiviral vector gene transfer efficacy.
FAP-CAR-T cells reduce dystrophic muscle fibrosis, improving adeno-associated virus gene transfer efficacy.
Correction: Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium.
Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trials
Peripheral Cellular Immune Responses Induced by Subretinal Adeno-Associated Virus Gene Transfer Can Be Restrained by the Subretinal-Associated Immune Inhibition Mechanism.
Cyclosporin H Improves the Transduction of CD34<sup>+</sup> Cells with an Anti-Sickling Globin Vector, a Possible Therapeutic Approach for Sickle Cell Disease.
Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome
Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome.
Severe hematopoietic stem cell inflammation compromises chronic granulomatous disease gene therapy.
Evaluation of diversity indices to estimate clonal dominance in gene therapy studies.
Recent advances in hematopoietic gene therapy for genetic disorders.
Recent Advances Using Genetic Therapies Against Infectious Diseases and for Vaccination.
Cellular Immune Responses Induced by Subretinal AAV Gene Transfer can be Restrained by the Subretinal Associated Immune Inhibition Mechanism
Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome.
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models.
Lentiviral standards to determine the sensitivity of assays that quantify lentiviral vector copy numbers and genomic insertion sites in cells.
Hematopoietic stem and progenitors cells gene editing: Beyond blood disorders.
Single-hit genome edition for expression of single-chain immunoglobulins by edited B cells
Author Correction: Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome.
Lentiviral gene therapy for X-linked chronic granulomatous disease
Lentiviral gene therapy for X-linked chronic granulomatous disease.
Clonal tracking in gene therapy patients reveals a diversity of human hematopoietic differentiation programs